News ASH: Regeneron plays its PNH hand Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.
News Regeneron is off to CHAPLE as FDA starts pozelimab review The C5 inhibitor is vying to become the first approved drug for the ultra-rare immune disorder.
News GSK ends decades-long hiatus in oral antibiotics for UTIs The FDA has approved GSK's Blujepa, the first new-mechanism oral antibiotic for uncomplicated UTIs in nearly 30 years, after a priority review.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
